Breast Cancer

The Department has no plans to conduct an equalities impact assessment on the National Institute for Health and Care Excellence (NICE) severity modifier, or to undertake a review of its adequacy in the context of secondary breast cancer.

The NICE is responsible for developing the methods and processes it uses in its evaluations independently and in consultation with stakeholders. The severity modifier that the NICE introduced in 2022 is based on evidence of societal preferences and was introduced as part of a comprehensive review of the NICE’s methods and processes, following extensive public and stakeholder engagement. The NICE considered equality issues in an equality impact document that accompanied the introduction of its new methods and processes, including the severity modifier.

The NICE recently concluded a review of the severity modifier and found that it is operating as intended. Since its introduction, the severity modifier has resulted in a higher approval rate for cancer medicines than under the NICE’s previous methods, and has also allowed greater weight to be applied to non-cancer medicines that address a broader range of severe diseases, enabling the NICE to recommend medicines for conditions such as cystic fibrosis and hepatitis D. The NICE is keeping the impact of the severity modifier under review and is scoping further research into society’s preferences on how much additional weighting to give to health benefits for people with severe diseases.